Unexpected news of a potential support program from the federal government boosted the share prices of weight-loss drug developers on Friday. The poster boy for that still rather small group, Wegov...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Novo To Contact Him Directly To Discuss Their Options If you su...

Shares in Wegovy maker Novo Nordisk fell around 4% on Friday to their lowest since August 2021, after U.S. President Donald Trump sent letters to major pharmaceutical firms to cut drug prices in th...

Novo Nordisk's weight loss drugs Ozempic and Wegovy transformed the firm into a global pharmaceutical giant. But four years after Wegovy's US launch, the Danish drugmaker's market value has plummeted.

Shares in Novo Nordisk (NYSE:NVO) are under the spotlight after a surprise profit warning, which, while denting the share price, failed to the wreak the damage some might have feared. That said, th...

Shares in Wegovy maker Novo Nordisk continued to slide on Wednesday as analysts warned of persistent competition from copycat drugs in the U.S., a day after a profit warning and the naming of a new...

Novo, which became Europe's most valuable listed company following the launch of Wegovy in 2021, is now facing a reckoning as it looks to turn things around after the abrupt removal in May of CEO L...

Bagsværd, Denmark, 29 July 2025 – Novo Nordisk today announced that Maziar Mike Doustdar has been appointed as president and chief executive officer, effective 7 August 2025. Mike Doustdar succeeds...

A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will need to show more robust growth in the months ahead to bolster market con...

Bagsværd, Denmark, 25 July 2025 – Novo Nordisk today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommendin...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Healthcare stocks have lagged the S&P 500, with Novo Nordisk already hit hard by intense competition from Eli Lilly. Despite recent setbacks and a decelerating growth outlook, Novo Nordisk's valuat...

Investors looking to strike while the iron is hot can buy beaten-down stocks that appear to have excellent chances of bouncing back. And that describes shares of Novo Nordisk (NVO -1.50%) very well.

Fangzhou Inc., a leader in Internet healthcare solutions, signed a Memorandum of Understanding with Novo Nordisk, a leading global healthcare company.

Novo Nordisk's Q1 2025 results were solid, but FY guidance was cut, suggesting a longer recovery. Large growth potential exists, with 85% of diabetes patients undertreated and obesity treatments un...